Literature DB >> 9196255

Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study.

G Fontanini1, M Lucchi, S Vignati, A Mussi, F Ciardiello, M De Laurentiis, S De Placido, F Basolo, C A Angeletti, G Bevilacqua.   

Abstract

BACKGROUND: Tumors acquire nutrients that are essential for continued growth and an avenue for dissemination to the rest of the body by inducing angiogenesis (i.e., the formation of new blood vessels). Preliminary studies involving a number of different kinds of cancer have indicated that an assessment of tumor angiogenesis may be useful in predicting disease outcome.
PURPOSE: In a prospective study, we evaluated the relationship between tumor angiogenesis and survival for 407 patients with non-small-cell lung carcinoma who were treated with potentially curative surgery.
METHODS: The study population consisted of 360 male and 47 female patients who underwent surgery consecutively at the Department of Surgery, University of Pisa, Italy, from March 1991 through December 1994. Follow-up lasted through February 1996, with a median follow-up for living patients of 29 months (range, 15-60 months). An anti-CD34 monoclonal antibody, which is specific for endothelial cells, and standard immunohistochemical techniques were used to measure angiogenesis in tumor samples. Angiogenesis was quantified in terms of microvessel counts; the counts for single, high-power microscopic fields (magnification x250) in the three most intense areas of blood vessel growth for each sample were averaged. The median microvessel count in this series was 20, and the counts were categorized as follows: 1) low versus high (< or =20 versus >20 microvessels) or 2) in five categories (1-10, 11-20, 21-30, 31-40, and > or =41 microvessels). Disease-free and overall survival during follow-up were assessed. Kaplan-Meier survival curves were modeled in a univariate analysis of patient and tumor characteristics; the Cox proportional hazards model was used in multivariate analysis. Reported P values are two-sided. RESULTS AND
CONCLUSIONS: In the univariate analysis, patients with larger tumors (P for trend <.00001), a more advanced tumor stage (P for trend <.00001), a greater degree of regional lymph node involvement (P for trend <.00001), or more vascularized tumors (high versus low microvessel count, P<.00001) experienced significantly reduced overall survival. When microvessel counts were analyzed in five categories, a highly significant trend (P<.00001) toward worse prognosis was observed with increasing tumor vascularity. In multivariate analysis, tumor microvessel count (P<.00001), tumor size (P = .0006), and regional lymph node status (P<.00001) retained independent prognostic value with respect to overall survival; among these variables, tumor microvessel count, considered as a continuous variable, was the most important, with a relative hazard of death of 8.38 (95% confidence interval = 4.19-16.78) associated with the highest microvessel counts. IMPLICATIONS: An evaluation of tumor angiogenesis may be useful in the postsurgical staging of patients with non-small-cell lung carcinoma and in identifying subsets of patients who may benefit from different postsurgical treatments.

Entities:  

Mesh:

Year:  1997        PMID: 9196255     DOI: 10.1093/jnci/89.12.881

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  54 in total

Review 1.  Lung cancer therapeutics that target signaling pathways: an update.

Authors:  M Roshni Ray; David Jablons; Biao He
Journal:  Expert Rev Respir Med       Date:  2010-10       Impact factor: 3.772

Review 2.  Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

Authors:  S A Kono; L E Heasley; R C Doebele; D R Camidge
Journal:  Curr Cancer Drug Targets       Date:  2012-02       Impact factor: 3.428

Review 3.  Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer.

Authors:  Seiji Yano; Yuka Matsumori; Kenji Ikuta; Hirokazu Ogino; Tamir Doljinsuren; Saburo Sone
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

Review 4.  Endothelial progenitor cells: current issues on characterization and challenging clinical applications.

Authors:  Thomas Resch; Andreas Pircher; Christian M Kähler; Johann Pratschke; Wolfgang Hilbe
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

5.  Perfusion computed tomography evaluation of angiogenesis in liver cancer.

Authors:  Han Feng Yang; Yong Du; Jia Xiang Ni; Xiang Ping Zhou; Jin Dong Li; Qing Zhang; Xiao Xue Xu; Yang Li
Journal:  Eur Radiol       Date:  2010-02-24       Impact factor: 5.315

Review 6.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

7.  Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis.

Authors:  W Hilbe; S Dirnhofer; F Oberwasserlechner; W Eisterer; K Ammann; T Schmid; G Hilbe; J Thaler; E Wöll
Journal:  J Clin Pathol       Date:  2003-10       Impact factor: 3.411

8.  The prognostic value of platelet endothelial cell adhesion molecule-1 in non-small-cell lung cancer patients.

Authors:  Bo-hua Kuang; Xi-zhi Wen; Ya Ding; Rui-qing Peng; Pei-qiang Cai; Meng-qing Zhang; Feng Jiang; Xiao-shi Zhang; Xing Zhang
Journal:  Med Oncol       Date:  2013-03-15       Impact factor: 3.064

9.  CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer.

Authors:  W Hilbe; S Dirnhofer; F Oberwasserlechner; T Schmid; E Gunsilius; G Hilbe; E Wöll; C M Kähler
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

10.  Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.

Authors:  Kwang Woon Kim; Luigi Moretti; Lauren Rhea Mitchell; Dae Kwang Jung; Bo Lu
Journal:  Clin Cancer Res       Date:  2009-09-22       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.